The integration of positron emission tomography (PET) imaging with cerebrospinal fluid (CSF) and blood-based biomarkers represents a cornerstone of modern Alzheimer's disease (AD) biomarker research. This approach combines the excellent spatial resolution and in vivo pathology visualization of PET with the molecular specificity and sensitivity of fluid biomarkers.
The combination enables researchers to:
- Validate biomarker equivalence - Confirm that fluid biomarkers accurately reflect brain pathology visible on PET
- Understand temporal sequences - Map the order in which biomarker abnormalities occur
- Improve diagnostic accuracy - Combine imaging and fluid data for more precise diagnoses
- Enrich clinical trials - Use biomarker combinations to identify optimal patient populations
Studies presented at AAIC 2026 demonstrated:
- High concordance between amyloid PET positivity and CSF Aβ42/40 ratio (85-95% agreement)
- Discordance patterns provide biological insights - some individuals with positive PET have normal CSF and vice versa
- CSF Aβ42/40 as a reliable screening tool to identify amyloid-positive individuals for PET imaging
The relationship between tau PET and CSF phosphorylated tau (p-tau) was a major focus:
- Strong correlation between regional tau PET uptake and CSF p-tau181/p-tau217 levels
- p-tau217 shows particularly high correlation with tau PET in neocortical regions
- Regional specificity - CSF p-tau may detect earlier tau changes than PET
Integration of imaging and fluid biomarkers for neurodegeneration:
- MRI atrophy patterns combined with NfL provide complementary information
- FDG-PET hypometabolism correlates with CSF NfL in advanced disease
- Multimodal markers improve prediction of cognitive decline
The NIA-AA Research Framework uses biomarker categories:
| Category |
Imaging Biomarkers |
Fluid Biomarkers |
| A (Amyloid) |
Amyloid PET |
CSF Aβ42/40, Aβ42 |
| T (Tau) |
Tau PET |
CSF p-tau181, p-tau217 |
| (N) (Neurodegeneration) |
MRI, FDG-PET |
CSF/serum NfL, t-tau |
| Profile |
Amyloid |
Tau |
Neurodegeneration |
| AD |
+ |
+ |
+ |
| AD path, no neurodegeneration |
+ |
+ |
- |
| Non-AD pathologic change |
- |
+ or - |
+ |
- Use CSF screening to reduce unnecessary PET scans
- Sequential testing strategies for clinical diagnosis
- Blood-based biomarkers as initial screening tools
- Standardization of CSF assays across laboratories
- PET quantification harmonization (e.g., Centiloid project)
- Cross-platform validation studies